Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms

NCT: NCT05285553 · ACTIVE_NOT_RECRUITING

NCT IDNCT05285553
StatusACTIVE_NOT_RECRUITING
Start Date2022-06-25
Completion2030-06-30
SponsorCooperVision, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.

Frequently Asked Questions

What is MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms?

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms is a clinical trial registered under NCT05285553. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05285553?

The current status of NCT05285553 (MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms) is: ACTIVE_NOT_RECRUITING.

When did MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms start?

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms started on 2022-06-25.

Related Devices

PMA P180035Daily wear soft contact lens to reduce the progression of myopiaCooperVision, Inc. K181920Clariti 1 day (somofilcon A) Soft (Hydrophilic) Daily Disposable Contact Lens with UV BlockerCooperVision, Inc. K234127Clariti 1 day Multifocal (somofilcon A) Soft (Hydrophilic), Daily Disposable Contact Lens with UV BlockerCooperVision, Inc. K160803Avaira Vitality (fanfilcon A) Soft (Hydrofilic) Contact LensCooperVision, Inc. K190965MyDayCooperVision, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑